Cargando…
The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The uniq...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898678/ https://www.ncbi.nlm.nih.gov/pubmed/33628170 http://dx.doi.org/10.3389/fphar.2020.578823 |
_version_ | 1783653913856049152 |
---|---|
author | Taheri, Yasaman Joković, Nataša Vitorović, Jelena Grundmann, Oliver Maroyi, Alfred Calina, Daniela |
author_facet | Taheri, Yasaman Joković, Nataša Vitorović, Jelena Grundmann, Oliver Maroyi, Alfred Calina, Daniela |
author_sort | Taheri, Yasaman |
collection | PubMed |
description | Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The unique cell entry and stability to β-lactamases allow cefiderocol to overcome the most common resistance mechanisms in Gram-negative bacteria. Objective: This article aims to highlight the therapeutic efficacy, safety and tolerability of cefiderocol, with a focus on the FDA label. Methods: The pharmacological properties of cefiderocol are also summarized. In this review, we conducted literature research on the PubMed database using the following keywords: “antimicrobial treatment”, “new antibiotic”, “cefiderocol”, “siderophore cephalosporin”; “multidrug-resistant”, “Gram-negative bacilli”, “critically ill patients”; “severe bacterial infections”. Results: There were identified the most relevant data about the pathophysiology of serious bacterial infections, antibacterial mechanism of action, microbiology, mechanisms of resistance, pharmacokinetic and pharmacodynamic properties of cefiderocol. Conclusion: The results highlighted there appeared to be clinical benefit from cefiderocol in the treatment of infections caused by Gram-negative aerobic microorganisms in adult patients with severe infections and limited treatment options. |
format | Online Article Text |
id | pubmed-7898678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78986782021-02-23 The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol Taheri, Yasaman Joković, Nataša Vitorović, Jelena Grundmann, Oliver Maroyi, Alfred Calina, Daniela Front Pharmacol Pharmacology Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The unique cell entry and stability to β-lactamases allow cefiderocol to overcome the most common resistance mechanisms in Gram-negative bacteria. Objective: This article aims to highlight the therapeutic efficacy, safety and tolerability of cefiderocol, with a focus on the FDA label. Methods: The pharmacological properties of cefiderocol are also summarized. In this review, we conducted literature research on the PubMed database using the following keywords: “antimicrobial treatment”, “new antibiotic”, “cefiderocol”, “siderophore cephalosporin”; “multidrug-resistant”, “Gram-negative bacilli”, “critically ill patients”; “severe bacterial infections”. Results: There were identified the most relevant data about the pathophysiology of serious bacterial infections, antibacterial mechanism of action, microbiology, mechanisms of resistance, pharmacokinetic and pharmacodynamic properties of cefiderocol. Conclusion: The results highlighted there appeared to be clinical benefit from cefiderocol in the treatment of infections caused by Gram-negative aerobic microorganisms in adult patients with severe infections and limited treatment options. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7898678/ /pubmed/33628170 http://dx.doi.org/10.3389/fphar.2020.578823 Text en Copyright © 2021 Taheri, Joković, Vitorović, Grundmann, Maroyi and Calina. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Taheri, Yasaman Joković, Nataša Vitorović, Jelena Grundmann, Oliver Maroyi, Alfred Calina, Daniela The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol |
title | The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol |
title_full | The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol |
title_fullStr | The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol |
title_full_unstemmed | The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol |
title_short | The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol |
title_sort | burden of the serious and difficult-to-treat infections and a new antibiotic available: cefiderocol |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898678/ https://www.ncbi.nlm.nih.gov/pubmed/33628170 http://dx.doi.org/10.3389/fphar.2020.578823 |
work_keys_str_mv | AT taheriyasaman theburdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT jokovicnatasa theburdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT vitorovicjelena theburdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT grundmannoliver theburdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT maroyialfred theburdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT calinadaniela theburdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT taheriyasaman burdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT jokovicnatasa burdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT vitorovicjelena burdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT grundmannoliver burdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT maroyialfred burdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol AT calinadaniela burdenoftheseriousanddifficulttotreatinfectionsandanewantibioticavailablecefiderocol |